Mylan/AHP Maxzide agreement will return product rights to Mylan in five years.
Executive Summary
MYLAN WILL REGAIN EXCLUSIVE RIGHTS TO MAXZIDE FROM AMERICAN HOME PRODUCTS in five years under an agreement covering the triamterene/hydrochlorothiazide products Maxzide and Maxzide-25 announced July 2. After a five-year transition during which Mylan "will pay American Home Products specific amounts," all "financial obligations stop and Mylan will retain all rights to the products, trademarks and tradedress," Mylan said. AHP will continue to market the products in Europe. Generic competition to Maxzide is just beginning: Sidmak's ANDA for a version of Maxzide-25 was approved April 26.